349 related articles for article (PubMed ID: 20933038)
1. Improved in silico prediction of carcinogenic potency (TD50) and the risk specific dose (RSD) adjusted Threshold of Toxicological Concern (TTC) for genotoxic chemicals and pharmaceutical impurities.
Contrera JF
Regul Toxicol Pharmacol; 2011 Feb; 59(1):133-41. PubMed ID: 20933038
[TBL] [Abstract][Full Text] [Related]
2. In silico approaches to predicting cancer potency for risk assessment of genotoxic impurities in drug substances.
Bercu JP; Morton SM; Deahl JT; Gombar VK; Callis CM; van Lier RB
Regul Toxicol Pharmacol; 2010; 57(2-3):300-6. PubMed ID: 20363275
[TBL] [Abstract][Full Text] [Related]
3. Quantitative assessment of cumulative carcinogenic risk for multiple genotoxic impurities in a new drug substance.
Bercu JP; Hoffman WP; Lee C; Ness DK
Regul Toxicol Pharmacol; 2008 Aug; 51(3):270-7. PubMed ID: 18550240
[TBL] [Abstract][Full Text] [Related]
4. Prediction of rodent carcinogenic potential of naturally occurring chemicals in the human diet using high-throughput QSAR predictive modeling.
Valerio LG; Arvidson KB; Chanderbhan RF; Contrera JF
Toxicol Appl Pharmacol; 2007 Jul; 222(1):1-16. PubMed ID: 17482223
[TBL] [Abstract][Full Text] [Related]
5. Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR models.
Contrera JF; Kruhlak NL; Matthews EJ; Benz RD
Regul Toxicol Pharmacol; 2007 Dec; 49(3):172-82. PubMed ID: 17703860
[TBL] [Abstract][Full Text] [Related]
6. Potentially mutagenic impurities: analysis of structural classes and carcinogenic potencies of chemical intermediates in pharmaceutical syntheses supports alternative methods to the default TTC for calculating safe levels of impurities.
Galloway SM; Vijayaraj Reddy M; McGettigan K; Gealy R; Bercu J
Regul Toxicol Pharmacol; 2013 Aug; 66(3):326-35. PubMed ID: 23688841
[TBL] [Abstract][Full Text] [Related]
7. Recent developments in the risk assessment of potentially genotoxic impurities in pharmaceutical drug substances.
Humfrey CD
Toxicol Sci; 2007 Nov; 100(1):24-8. PubMed ID: 17656486
[TBL] [Abstract][Full Text] [Related]
8. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity.
Müller L; Mauthe RJ; Riley CM; Andino MM; Antonis DD; Beels C; DeGeorge J; De Knaep AG; Ellison D; Fagerland JA; Frank R; Fritschel B; Galloway S; Harpur E; Humfrey CD; Jacks AS; Jagota N; Mackinnon J; Mohan G; Ness DK; O'Donovan MR; Smith MD; Vudathala G; Yotti L
Regul Toxicol Pharmacol; 2006 Apr; 44(3):198-211. PubMed ID: 16412543
[TBL] [Abstract][Full Text] [Related]
9. Overview of genotoxic impurities in pharmaceutical development.
Bercu JP; Dobo KL; Gocke E; McGovern TJ
Int J Toxicol; 2009; 28(6):468-78. PubMed ID: 19966139
[TBL] [Abstract][Full Text] [Related]
10. Validation of Toxtree and SciQSAR in silico predictive software using a publicly available benchmark mutagenicity database and their applicability for the qualification of impurities in pharmaceuticals.
Contrera JF
Regul Toxicol Pharmacol; 2013 Nov; 67(2):285-93. PubMed ID: 23969001
[TBL] [Abstract][Full Text] [Related]
11. Characterization and validation of an in silico toxicology model to predict the mutagenic potential of drug impurities.
Valerio LG; Cross KP
Toxicol Appl Pharmacol; 2012 May; 260(3):209-21. PubMed ID: 22426359
[TBL] [Abstract][Full Text] [Related]
12. Mutagenic impurities in pharmaceuticals: a critique of the derivation of the cancer TTC (Threshold of Toxicological Concern) and recommendations for structural-class-based limits.
Snodin DJ; McCrossen SD
Regul Toxicol Pharmacol; 2013 Nov; 67(2):299-316. PubMed ID: 23988886
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the genotoxic and carcinogenic risks of p-nitrophenol when it is present as an impurity in a drug product.
Eichenbaum G; Johnson M; Kirkland D; O'Neill P; Stellar S; Bielawne J; DeWire R; Areia D; Bryant S; Weiner S; Desai-Krieger D; Guzzie-Peck P; Evans DC; Tonelli A
Regul Toxicol Pharmacol; 2009 Oct; 55(1):33-42. PubMed ID: 19500632
[TBL] [Abstract][Full Text] [Related]
14. An impact analysis of the application of the threshold of toxicological concern concept to pharmaceuticals.
Delaney EJ
Regul Toxicol Pharmacol; 2007 Nov; 49(2):107-24. PubMed ID: 17888551
[TBL] [Abstract][Full Text] [Related]
15. Testing computational toxicology models with phytochemicals.
Valerio LG; Arvidson KB; Busta E; Minnier BL; Kruhlak NL; Benz RD
Mol Nutr Food Res; 2010 Feb; 54(2):186-94. PubMed ID: 20024931
[TBL] [Abstract][Full Text] [Related]
16. Approaches to the risk assessment of genotoxic carcinogens in food: a critical appraisal.
O'Brien J; Renwick AG; Constable A; Dybing E; Müller DJ; Schlatter J; Slob W; Tueting W; van Benthem J; Williams GM; Wolfreys A
Food Chem Toxicol; 2006 Oct; 44(10):1613-35. PubMed ID: 16887251
[TBL] [Abstract][Full Text] [Related]
17. Comparison of carcinogenic and in vivo genotoxic potency estimates.
Sanner T; Dybing E
Basic Clin Pharmacol Toxicol; 2005 Feb; 96(2):131-9. PubMed ID: 15679476
[TBL] [Abstract][Full Text] [Related]
18. A novel QSAR model of Salmonella mutagenicity and its application in the safety assessment of drug impurities.
Valencia A; Prous J; Mora O; Sadrieh N; Valerio LG
Toxicol Appl Pharmacol; 2013 Dec; 273(3):427-34. PubMed ID: 24090816
[TBL] [Abstract][Full Text] [Related]
19. Role of in silico genotoxicity tools in the regulatory assessment of pharmaceutical impurities.
Fioravanzo E; Bassan A; Pavan M; Mostrag-Szlichtyng A; Worth AP
SAR QSAR Environ Res; 2012; 23(3-4):257-77. PubMed ID: 22369620
[TBL] [Abstract][Full Text] [Related]
20. The Threshold of Toxicological Concern (TTC) in risk assessment.
Munro IC; Renwick AG; Danielewska-Nikiel B
Toxicol Lett; 2008 Aug; 180(2):151-6. PubMed ID: 18573621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
